GO
Loading...

Medicine

More

  • Diabetes Drug Safety: Has Another Red Flag Been Raised? Wednesday, 6 Feb 2008 | 3:07 PM ET

    Reaction to part of a big government-sponsored diabetes drug study being halted over fatalities is pouring in from several corners. The American Diabetes Association put out a press release saying it "strongly encourages people with diabetes not to alter their course of treatment without first consulting with their health care team...

  • Biogen Idec Draws "Line In The Sand" With Carl Icahn Wednesday, 6 Feb 2008 | 11:28 AM ET

    I'm blogging a little later than usual because I got sidetracked by the breaking news on the government stopping part of a big diabetes drug study over safety concerns--more people died in a group that was being intensively treated to get their blood sugar levels below current recommendations.

  • Drug Stocks: Real Downers And At A Two-Year Low Tuesday, 5 Feb 2008 | 4:29 PM ET

    Yes, it was a big down day for equities, but I wanted to call attention to the fact that according to one of our resident stock gurus, Robert Hum, the Amex Pharmaceutical Index (you can see the 15 stocks that make up the so-called DRG here) closed at a two-year low today.

  • Boston Scientific And The "Struggling" Stents Tuesday, 5 Feb 2008 | 10:25 AM ET

    Sales of drug-coated stents, Boston Scientific's most profitable products, came in at the low end of the company's guidance in the fourth quarter. Stents are the fragile little wire mesh cylinders that act like scaffolding to prop open clogged arteries.

  • FDA At Level "Orange" Safety Warning? Monday, 4 Feb 2008 | 2:14 PM ET

    The Food and Drug Administration continues to get a lot of attention and scrutiny. In an editorial over the weekend "The New York Times" wrote, "The F.D.A. desperately needs an infusion of money and talent." Then, "USA Today" today is running a front-page article on something I recently blogged about and other reporters tackled a few weeks ago regarding the agency approving so few drugs last year.

  • Pfizer's Chantix Suffers Yet Another Blow From FDA Friday, 1 Feb 2008 | 4:53 PM ET

    Pfizer tried to get out in front of the psychiatric side-effect issues on its stop-smoking drug by adding information about behavioral changes, mood swings, thoughts of suicide, etc. to the label last month.

  • Glaxo, Merck, SGP & Amgen: Readers Have a Lot to Say Friday, 1 Feb 2008 | 10:51 AM ET

    It's a new month. Time to clean out the inbox. Regarding my post earlier this week about Sen. Chuck Grassley's office breaking the "Nature" embargo on the leak of the GlaxoSmithKline Avandia study, I heard from the "Nature" article reporter.

  • Bristol-Myers' Disappearing Penny: Case Is Now Closed Thursday, 31 Jan 2008 | 2:42 PM ET

    I just got off the phone with the Chief Operating Officer of PR Newswire, Dave Armon, who says the discrepancy between the two Bristol-Myers Squibb earnings press releases I've been blogging about was due to an information technology glitch at PR Newswire.

  • This morning on "Squawk on the Street" I did a pharma earnings round-up report and I topped it by saying the sector could remain under pressure today because two major American drug companies--Bristol-Myers Squibb and Wyeth-- missed earnings expectations and lowered their 2008 guidance.

  • Glaxo's Avandia Leak: Who Really Broke Embargo? Wednesday, 30 Jan 2008 | 4:59 PM ET
    GlaxoSmithKline's Avandia

    At 1 pm ET today the embargo was supposed to lift on an article in the scientific journal "Nature" that we got advanced word on early this morning. We were set to post the write-through about it at that time on our web site.

  • Merck: Why's Stock So Low? (And What Am I Missing?) Wednesday, 30 Jan 2008 | 12:10 PM ET

    Dow component Merck beat the Street with fourth quarter results on earnings per share (revenue was a sliver below the analyst consensus) and reaffirmed its earnings guidance for this year. Maybe the beaten-down stock is falling victim to another pre-Fed interest rate decision market downdraft...

  • "Dendreonians" were hoping the Provenge controversy might come up for discussion at the House Energy and Commerce Committee's Subcommittee on Oversight and Investigations hearing today.

  • Lilly & Amylin's Byetta Ad Buys Don't Pay Off Tuesday, 29 Jan 2008 | 10:27 AM ET
    Byetta Needle

    Direct-to-consumer pharmaceutical advertising is everywhere in American media because it works. Generally speaking, it drives patients to ask/tell their doctors to prescribe a particular medication.

  • In what I would describe as a pretty extraordinary filing with the Securities and Exchange Commission, Schering-Plough is putting in black and white the date and time that senior level executives were informed about the results of the controversial ENHANCE study of the cholesterol drug Vytorin.

  • Friday I blogged about the most audacious press release I've received in a long time from a small biomed company called GenoMed. The company's Chairman and CEO, Dr. David Moskowitz, claims Heath Ledger probably died due to complications from the flu--likening it to Anna Nicole Smith's death--and GenoMed had the means to save him.

  • A $4 billion company I've never covered before, Inverness Medical Innovations, is making news this morning with a $900 million acquisition of another company I've never covered--Matria Healthcare, Inc. But that's not why I'm blogging about Inverness.

  • FDA Speaks on Merck & Schering's Vytorin Friday, 25 Jan 2008 | 6:59 PM ET

    I listened in to the hour-long Food and Drug Administration conference call with reporters regarding Vytorin, and I wanted to pass along a few highlights...

  • In the wake of my semantic disagreement with Amgen over whether it beat, met or missed its earnings pre-announcement earlier this month, analysts are putting out research notes to clients on the company's results, guidance and new drug data and blog readers are sending emails about my take on the full year 2007 number.

  • AMGEN

    I just got back to my desk after doing a breaking news alert on Amgen's earnings. To sum up, I characterized the report as a mixed bag. The anemia drug sales weren't as bad as expected. Overall revenue was higher than consensus. And fourth quarter earnings per share was three cents higher than the Street.

  • Merck And Schering Reeling From Vytorin Study Thursday, 24 Jan 2008 | 1:56 PM ET

    ImpactRx--which follows prescription writing for the industry, investors and analysts--is out with a press release this afternoon assessing the damage to Merck and Schering-Plough's cholesterol franchise of Vytorin and Zetia.